CVX vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Chevron Corporation and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-25.
Chevron Corporation · Energy
$205.52
+35.9% upside to fair value
Med Conviction
Grade B
High Quality
VS
Johnson & Johnson · Healthcare
$270.68
+5.7% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
CVX has more upside to fair value
(+35.9%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CVX |
JNJ |
| Current Price |
$205.52 |
$270.68 |
| Fair Value Estimate |
$279.29 |
$286.05 |
| Upside to Fair Value |
+35.9%
|
+5.7%
|
| Market Cap |
$409.3B |
$652.3B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
7.8x
|
20.2x
|
| Price / Sales |
2.0x
|
6.7x
|
| Price / FCF |
15.0x
|
35.3x
|
| Revenue Growth YoY |
+51.4%
|
+6.6%
|
| Gross Margin |
31.0%
|
67.9%
|
| Operating Margin |
15.8%
|
26.8%
|
| Return on Equity |
11.0%
|
25.7%
|
| Dividend Yield |
3.43% |
1.95% |
| FCF Yield |
6.67%
|
2.83%
|
| Analyst Consensus |
Buy
|
Buy
|
Investment Thesis
Chevron is a global integrated oil and gas major organized into Upstream and Downstream segments, spanning crude oil and natural gas exploration, LNG processing and transport, refining, petrochemicals, and lubricants, with 43,039 full-time employees and a market capitalization of $409.31 billion at a current price of $205.52. The business quality is high: it generates $13.71 of free cash flow per…
Johnson & Johnson is a 141,700-employee healthcare holding company operating two segments, Innovative Medicine (immunology, oncology, neuroscience, infectious disease, cardiovascular and metabolism, pulmonary hypertension) and MedTech (interventional solutions, orthopaedics, surgery, vision), founded in 1887 and headquartered in New Brunswick, New Jersey. Business quality is high on fundamentals:…
Accumulation Zones
| Metric |
CVX |
JNJ |
| Zone Low |
$209.47 |
$214.54 |
| Zone High |
$237.40 |
$243.14 |
| In Buy Zone? |
Yes
|
No
|